Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Armoiry

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
International Journal of Laboratory Hematology|March 7, 2023
ICSH guidance for INR and D-dimer testing using point of care testing in primary careDavid A Fitzmaurice, Geert-Jan Geersing, Xavier Armoiry, et al.
Therapie|April 23, 2015
[Capsaicin Cutaneous Patch: a Cost-consequences Study in a French University Hospital]Maud Schweitzer, Jean-Bernard Caillet, Carole Paillet, et al.
Plos One|June 16, 2026
Transcatheter and surgical aortic valve replacement for aortic stenosis in France: Trends from 2010 to 2022 and impact of European guidelines and clinical trial resultsAnaïs Havet, Annaëlle Testud, Aubane L'Hospital, et al.
Journal of Clinical Epidemiology|October 16, 2020
High-dimensional propensity scores improved the control of indication bias in surgical comparative effectiveness studiesCécile Payet, Stéphanie Polazzi, Jean-François Obadia, et al.
Systematic Reviews|May 23, 2016
The magnitude and mechanisms of the weekend effect in hospital admissions: A protocol for a mixed methods review incorporating a systematic review and framework synthesisYen-Fu Chen, Amunpreet Boyal, Elizabeth Sutton, et al.
Pharmacoeconomics|February 13, 2020
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPeter Auguste, Jill Colquitt, Martin Connock, et al.
BMC Cancer|April 27, 2019
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trialsMartin Connock, Xavier Armoiry, Alexander Tsertsvadze, et al.
Pharmacoeconomics|March 28, 2018
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology AppraisalXavier Armoiry, Martin Connock, Alexander Tsertsvadze, et al.
ESC Heart Failure|May 12, 2026
Cost-effectiveness of TTVR with EVOQUE system in patients with Severe Tricuspid Regurgitation based on TRISCEND II trialApolline Grangeon, Martin Connock, Peter Auguste, et al.
International Journal of Technology Assessment in Health Care|December 13, 2022
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosisXavier Armoiry, Xia Wang-Steverding, Martin Connock, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
International Journal of Laboratory Hematology|March 7, 2023
ICSH guidance for INR and D-dimer testing using point of care testing in primary careDavid A Fitzmaurice, Geert-Jan Geersing, Xavier Armoiry, et al.
Therapie|April 23, 2015
[Capsaicin Cutaneous Patch: a Cost-consequences Study in a French University Hospital]Maud Schweitzer, Jean-Bernard Caillet, Carole Paillet, et al.
Plos One|June 16, 2026
Transcatheter and surgical aortic valve replacement for aortic stenosis in France: Trends from 2010 to 2022 and impact of European guidelines and clinical trial resultsAnaïs Havet, Annaëlle Testud, Aubane L'Hospital, et al.
Journal of Clinical Epidemiology|October 16, 2020
High-dimensional propensity scores improved the control of indication bias in surgical comparative effectiveness studiesCécile Payet, Stéphanie Polazzi, Jean-François Obadia, et al.
Systematic Reviews|May 23, 2016
The magnitude and mechanisms of the weekend effect in hospital admissions: A protocol for a mixed methods review incorporating a systematic review and framework synthesisYen-Fu Chen, Amunpreet Boyal, Elizabeth Sutton, et al.
Pharmacoeconomics|February 13, 2020
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPeter Auguste, Jill Colquitt, Martin Connock, et al.
BMC Cancer|April 27, 2019
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trialsMartin Connock, Xavier Armoiry, Alexander Tsertsvadze, et al.
Pharmacoeconomics|March 28, 2018
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology AppraisalXavier Armoiry, Martin Connock, Alexander Tsertsvadze, et al.
ESC Heart Failure|May 12, 2026
Cost-effectiveness of TTVR with EVOQUE system in patients with Severe Tricuspid Regurgitation based on TRISCEND II trialApolline Grangeon, Martin Connock, Peter Auguste, et al.
International Journal of Technology Assessment in Health Care|December 13, 2022
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosisXavier Armoiry, Xia Wang-Steverding, Martin Connock, et al.
Pageof 9